Knowledge Synergies Between Small Innovators Can Accelerate Drug Development, Experts Speak Out
This article was originally published in PharmAsia News
Executive SummarySINGAPORE - It may sound too idealistic but Israel Makov, Teva's former chief executive, believes the present drought of late-stage pipeline drugs can be filled if smaller companies doing research in "silos" share their specialized insights and form single entities to develop future drugs
You may also be interested in...
Sun Pharma promoter makes early investments that could yield future strategic value